Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox (Exjade) in 2–<6 year-old transfusion-dependent thalassemia with chronic iron overload
CTR20130108Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of deferasirox in beta thalassemia, iron overload, sponsored by Novartis. Started May 2014; status: completed.
02
Drugs
deferasirox
03
Conditions
beta thalassemiairon overload
Beyond the preview
Go deeper on CTR20130108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130108.